BioSpace News Archive

Biotech Bay

Vera Therapeutics to Present Phase 2a Data on Atacicept in IgA Nephropathy at the American Society of Nephrology Kidney Week 2021 Annual Meeting

Vera Therapeutics, Inc. announced today the upcoming presentation of clinical data for the Company’s lead product candidate, atacicept, from the Phase 2a JANUS clinical trial in patients with IgA nephropathy (IgAN).

October 13, 2021
·
1 min read
Business

LEXEO Therapeutics and FUJIFILM Diosynth Biotechnologies Announce Collaboration to Support Development and Manufacturing of Gene Therapies for Genetic Diseases

LEXEO Therapeutics and FUJIFILM Diosynth Biotechnologies today announced a strategic collaboration to support the development and manufacturing of LEXEO’s AAV-mediated gene therapies.

October 13, 2021
·
4 min read
BioMidwest

Abeona Therapeutics Announces Clinical Data Presentations at Upcoming Scientific Congresses

Abeona Therapeutics Inc. today announced two presentations of previously disclosed clinical data at upcoming scientific congresses in October 2021.

October 13, 2021
·
3 min read
Biotech Beach

Progenity Announces Several Patents Granted by USPTO, Strengthening the Company’s Intellectual Property Position in Ingestible Therapeutics Technologies

Progenity, Inc. announced today that the United States Patent and Trademark Office (USPTO) has issued four patents related to its ingestible technologies for delivery of therapeutics via the gastrointestinal (GI) tract.

October 13, 2021
·
7 min read
Business

Accuray to Report First Quarter Fiscal 2022 Financial Results on November 3, 2021

Accuray Incorporated (NASDAQ: ARAY) will report financial results for the first quarter of fiscal year 2022, ended September 30, 2021 , after the market close on Wednesday, November 3, 2021

October 13, 2021
·
1 min read
Drug Development

Apnimed Announces Positive Phase 2 Data (Study APC-004) Demonstrating Improvement in Measures of Obstructive Sleep Apnea and a Dose-Response with AD109, an Oral Pharmacologic Investigational Treatment for the Disease

Apnimed today announced positive data across multiple endpoints from its Phase 2 randomized, double-blind, placebo-controlled, crossover clinical trial (Study APC-004) evaluating the efficacy and safety of AD109 as a treatment for patients with mild to moderate OSA.

October 13, 2021
·
6 min read
Genetown

Alnylam Announces Launch of “Alnylam Challengers,” a Signature Community Impact Program to Improve Health Access to Underserved Communities

Alnylam Pharmaceuticals, Inc. today announced the launch of Alnylam Challengers, a signature community impact program that will support bold and diverse organizations in their pursuit of developing new and sustainable solutions to address challenges in health equity.

October 13, 2021
·
4 min read
Drug Development

Apnimed Announces Positive Phase 2 (Study APC-003) Data Demonstrating Durability-of-Effect and Improved Quality-of-Life in Patients with Obstructive Sleep Apnea After Investigational AD109 Treatment

Apnimed today announced positive data across multiple endpoints from a Phase 2 randomized, double-blind, placebo-controlled, four-period, single-dose crossover factorial clinical trial (APC-003), and a 28-day open-label extension study, evaluating AD109 as a treatment in patients with mild to severe OSA.

October 13, 2021
·
7 min read
Drug Development

Atara Biotherapeutics Presents New Magnetization Transfer Ratio Imaging Data and Two-Year Clinical Data from the Open Label Extension of ATA188 for Progressive Multiple Sclerosis at ECTRIMS 2021

Atara Biotherapeutics, Inc. today announced new translational data based on magnetization transfer ratio (MTR) and updated Phase 1 open-label extension (OLE) clinical data in patients with progressive multiple sclerosis (MS) treated with ATA188 for up to 39 months.

October 13, 2021
·
12 min read
Drug Development

Dyne Therapeutics Highlights Preclinical Data and Clinical Development Plans for DMD and DM1 Programs at Inaugural R&D Day

Dyne Therapeutics, Inc hosts its first Research and Development Day today focused on the Company’s co-lead development programs for rare muscle diseases, Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1).

October 13, 2021
·
6 min read